Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialLaura M. Spring, Aditya Bardia, Amy Comander et al.|Annals of Oncology|2023Cited by 77
Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Sheng Sun et al.|Clinical Cancer Research|2024Cited by 43
Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBCLaura M. Spring, Leif W. Ellisen, Bogang Wu et al.|Cancer Research|2024Cited by 2
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Sheng Sun et al.|Unknown|2024Cited by 1